Notably, the T cells activated by blinatumomab can induce serial killing of targeted tumor cells since the affinity of blinatumomab for CD3ε subunit (10−7 M) is much lower than that for CD19 (10−9 M) which increases the mobility of bound T cells13. The gene discussed is CD3E; the disease is neoplasm.